Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Surgery Plus Chemoradiotherapy for Esophageal Ca

Cochrane; 2017 Aug 22; Vellayappan, et al

Adding esophagectomy to chemoradiotherapy in locally advanced esophageal squamous cell carcinoma has little or no impact on overall survival, according to a Cochrane review of 2 randomized trials involving 431 individuals. Moreover, it may be linked with higher treatment-related mortality. Among the findings:

  • Adding surgery reduced the risk that cancer would come back at the primary site.
  • It did not improve overall survival.
  • There were more treatment-related deaths in patients who underwent surgery, vs those who didn’t.

The authors noted that adding esophagectomy probably delays locoregional relapse, but this end point was not well defined. They added that it is not known if these results can be applied to the treatment of adenocarcinomas, tumors of the distal esophagus and gastroesophageal junction, or to those who respond poorly to chemoradiation.


Vellayappan B, Soon Y, Ku G, Leong C, Lu J, Tey J. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. Cochrane Database of Systematic Reviews. 2017, Issue 8. Art. No.: CD010511. doi:10.1002/14651858.CD010511.pub2.

This Week's Must Reads

Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.

Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027

DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.

ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.

SRS can effectively control brain metastases in patients with RCC, Wardak Z et al. Clin Genitourin Cancer. 2018 Nov 20. doi: 10.1016/j.clgc.2018.11.006.

Must Reads in Head & Neck Cancers

Overall survival lower with cetuximab in oropharyngeal cancer, Mehanna H et al. ESMO 2018, Abstract LBA9_PR

Head and neck cancer therapy toxicities greater in women, Cristina V et al. JAMA Oncol. 2018 May 24. doi: 10.1001/jamaoncol.2018.1080.

CYCORE reduces radiotherapy side effects in head and neck cancers, Peterson et al. ASCO 2018, Abstract 6063

Metastatic Lymph Nodes and Oral Cancer Survival , J Clin Oncol; ePub 2017 Sep 7; Ho, Kim, et al